English  |  正體中文  |  简体中文  |  2833128  
???header.visitor??? :  34215264    ???header.onlineuser??? :  818
???header.sponsordeclaration???
 
臺灣學術機構典藏系統 (Taiwan Academic Institutional Repository, TAIR)
???ui.leftmenu.abouttair???

???ui.leftmenu.bartitle???

???index.news???

???ui.leftmenu.copyrighttitle???

???ui.leftmenu.link???

"tseng t c"???jsp.browse.items-by-author.description???

???jsp.browse.items-by-author.back???
???jsp.browse.items-by-author.order1??? ???jsp.browse.items-by-author.order2???

Showing items 181-205 of 534  (22 Page(s) Totally)
<< < 3 4 5 6 7 8 9 10 11 12 > >>
View [10|25|50] records per page

Institution Date Title Author
臺大學術典藏 2021-09-04T06:11:30Z Clinical significance of circulating miR-122 in patients with dual chronic hepatitis B and C virus infection Cheng H.-R.; JIA-HORNG KAO; Wu H.-L.; Tseng T.-C.; Liu C.-H.; Yang H.-C.; Su T.-H.; Chen P.-J.; Chen D.-S.; Liu C.-J.
臺大學術典藏 2021-09-04T06:11:29Z Treating Immune-tolerant Hepatitis B Tseng, T.-C.; JIA-HORNG KAO
臺大學術典藏 2021-09-04T06:11:28Z Adipocytokines and liver fibrosis stages in patients with chronic hepatitis B virus infection Hsu C.-S.; Liu W.-L.; Chao Y.-C.; Lin H.H.; Tseng T.-C.; Wang C.-C.; Chen D.-S.; JIA-HORNG KAO
臺大學術典藏 2021-09-04T06:11:28Z HBV-DNA level at 6 months of entecavir treatment predicts HBeAg loss in HBeAg-positive chronic hepatitis B patients Peng C.-Y.; Hsieh T.-C.; Hsieh T.-Y.; Tseng K.-C.; Lin C.-L.; Su T.-H.; Tseng T.-C.; Lin H.H.; Wang C.-C.; JIA-HORNG KAO
臺大學術典藏 2021-09-04T06:11:27Z Higher lifetime chance of spontaneous surface antigen loss in hepatitis B carriers with genotype C infection Tseng T.-C.; Liu C.-J.; Chen C.-L.; Yang W.-T.; Yang H.-C.; Su T.-H.; Wang C.-C.; Kuo S.F.-T.; Liu C.-H.; Chen P.-J.; Chen D.-S.; JIA-HORNG KAO
臺大學術典藏 2021-09-04T06:11:26Z Predicting hepatitis B virus (HBV) surface antigen seroclearance in HBV e antigen-negative patients with chronic hepatitis B: External validation of a scoring system Liu J.; Tseng T.-C.; Yang H.-I.; Lee M.-H.; Batrla-Utermann R.; Jen C.-L.; Lu S.-N.; Wang L.-Y.; You S.-L.; Chen P.-J.; Chen C.-J.; JIA-HORNG KAO
臺大學術典藏 2021-09-04T06:11:25Z Sorafenib and its derivative SC-1 exhibit antifibrotic effects through signal transducer and activator of transcription 3 inhibition Su T.-H.; Shiau C.-W.; Jao P.; Liu C.-H.; Liu C.-J.; Tai W.-T.; Jeng Y.-M.; Yang H.-C.; Tseng T.-C.; Huang H.-P.; Cheng H.-R.; Chen P.-J.; Chen K.-F.; JIA-HORNG KAO; Chen D.-S.
臺大學術典藏 2021-09-04T06:11:23Z Higher proportion of viral basal core promoter mutant increases the risk of liver cirrhosis in hepatitis B carriers Tseng T.-C.; Liu C.-J.; Yang H.-C.; Chen C.-L.; Yang W.-T.; Tsai C.-S.; Kuo S.F.-T.; Verbree F.C.; Su T.-H.; Wang C.-C.; Liu C.-H.; Chen P.-J.; Chen D.-S.; JIA-HORNG KAO
臺大學術典藏 2021-09-04T06:11:20Z Incorporating Serum Level of Hepatitis B Surface Antigen or Omitting Level of Hepatitis B Virus DNA Does not Affect Calculation of Risk for Hepatocellular Carcinoma in Patients Without Cirrhosis Yang H.-I.; Tseng T.-C.; Liu J.; Lee M.-H.; Liu C.-J.; Su T.-H.; Batrla-Utermann R.; Chan H.L.Y.; JIA-HORNG KAO; Chen C.-J.
臺大學術典藏 2021-09-04T06:11:18Z Hepatitis C viral infection increases the risk of lymphoid-neoplasms: A population-based cohort study Su T.-H.; Liu C.-J.; Tseng T.-C.; Chou S.-W.; Liu C.-H.; Yang H.-C.; Wu S.-J.; Chen P.-J.; Chen D.-S.; Chen C.-L.; JIA-HORNG KAO
臺大學術典藏 2021-09-04T06:11:17Z Hepatitis B surface antigen loss and hepatocellular carcinoma development in patients with dual hepatitis B and C infection Yang W.-T.; Wu L.-W.; Tseng T.-C.; Chen C.-L.; Yang H.-C.; Su T.-H.; Wang C.-C.; Kuo S.F.-T.; Liu C.-H.; Chen P.-J.; Chen D.-S.; Liu C.-J.; JIA-HORNG KAO
臺大學術典藏 2021-09-04T06:11:16Z Perspectives on dual hepatitis B and C infection in Taiwan Liu C.-J.; Chen P.-J.; Chen D.-S.; Tseng T.-C.; JIA-HORNG KAO
臺大學術典藏 2021-09-04T06:11:15Z Efficacy of entecavir therapy for hepatitis B e-antigen positive chronic hepatitis B patients with prior exposure to interferon or nucleoside/nucleotide analogues Tseng K.-C.; Tseng C.-W.; Hsieh T.-Y.; Peng C.-Y.; Lin C.-L.; Su T.-H.; Tseng T.-C.; Lin H.H.; Wang C.-C.; JIA-HORNG KAO
臺大學術典藏 2021-09-04T06:11:13Z Assessing the Durability of Entecavir-Treated Hepatitis B Using Quantitative HBsAg Wang C.-C.; Tseng K.-C.; Hsieh T.-Y.; Tseng T.-C.; Lin H.H.; JIA-HORNG KAO
臺大學術典藏 2021-09-04T06:11:09Z Prevalence and clinical implications of IL28B genotypes in Taiwanese patients with chronic hepatitis C Mah Y.-H.; Liu C.-H.; Chen C.-L.; Tseng T.-C.; Liu C.-J.; Chen P.-J.; Chen D.-S.; JIA-HORNG KAO
臺大學術典藏 2021-09-04T06:11:08Z Four-year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patients Su T.-H.; Hu T.-H.; Chen C.-Y.; Huang Y.-H.; Chuang W.-L.; Lin C.-C.; Wang C.-C.; Su W.-W.; Chen M.-Y.; Peng C.-Y.; Chien R.-N.; Huang Y.-W.; Wang H.-Y.; Lin C.-L.; Yang S.-S.; Chen T.-M.; Mo L.-R.; Hsu S.-J.; Tseng K.-C.; Hsieh T.-Y.; Suk F.-M.; Hu C.-T.; Bair M.-J.; Liang C.-C.; Lei Y.-C.; Tseng T.-C.; Chen C.-L.; JIA-HORNG KAO; the C-TEAM study group; the Taiwan Liver Diseases Consortium
臺大學術典藏 2021-09-04T06:11:03Z Elimination of Hepatitis B: Is It a Mission Possible? Tseng T.-C.; JIA-HORNG KAO
臺大學術典藏 2021-09-04T06:11:01Z HBV markers for HCC prediction: Three heads are better than two? Tseng T.-C.; JIA-HORNG KAO
臺大學術典藏 2021-09-04T06:11:01Z More viral mutants, less HBsAg clearance? One size may not fit all Tseng T.-C.; Yang H.-C.; JIA-HORNG KAO
臺大學術典藏 2021-09-04T06:10:59Z Fibrosis-4 Index Helps Identify HBV Carriers with the Lowest Risk of Hepatocellular Carcinoma Tseng T.-C.; Liu C.-J.; Su T.-H.; Yang W.-T.; Chen C.-L.; Yang H.-C.; Wang C.-C.; Kuo S.F.-T.; Liu C.-H.; Chen P.-J.; Chen D.-S.; JIA-HORNG KAO
臺大學術典藏 2021-09-04T06:10:59Z Impact of occult hepatitis B on the clinical outcomes of patients with chronic hepatitis C virus infection: A 10-year follow-up Chen H.-Y.; Su T.-H.; Tseng T.-C.; Yang W.-T.; Chen T.-C.; Chen P.-J.; Chen D.-S.; JIA-HORNG KAO; Liu C.-J.
臺大學術典藏 2021-09-04T06:10:55Z Src-homology protein tyrosine phosphatase-1 agonist, SC-43, reduces liver fibrosis Su T.-H.; Shiau C.-W.; Jao P.; Yang N.-J.; Tai W.-T.; Liu C.-J.; Tseng T.-C.; Yang H.-C.; Liu C.-H.; Huang K.-W.; Hu T.-C.; Huang Y.-J.; Wu Y.-M.; Chen L.-J.; Chen P.-J.; Chen D.-S.; Chen K.-F.; JIA-HORNG KAO
臺大學術典藏 2021-09-04T05:17:10Z Hepatitis b virus–specific t cells associate with viral control upon nucleos(t)ide-analogue therapy discontinuation Rivino L.; Le Bert N.; Gill U.S.; Kunasegaran K.; Cheng Y.; Tan D.Z.M.; Becht E.; Hansi N.K.; Foster G.R.; Su T.-H.; Tseng T.-C.; Lim S.G.; JIA-HORNG KAO; Newell E.W.; Kennedy P.T.F.; Bertoletti A.
臺大學術典藏 2021-09-04T05:17:09Z Real-world effectiveness and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir with or without ribavirin for patients with chronic hepatitis C virus genotype 1b infection in Taiwan Liu C.-H.; Liu C.-J.; Su T.-H.; Yang H.-C.; Hong C.-M.; Tseng T.-C.; Chen P.-J.; Chen D.-S.; JIA-HORNG KAO
臺大學術典藏 2021-09-04T05:17:08Z HCC risk in patients with HBV-related cirrhosis receiving nucleos(t)ide analogues therapy: Is HCC prevented or delayed? Su T.-H.; Tseng T.-C.; JIA-HORNG KAO

Showing items 181-205 of 534  (22 Page(s) Totally)
<< < 3 4 5 6 7 8 9 10 11 12 > >>
View [10|25|50] records per page